Skip to content

Lyell Immunopharma

Request correction

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer.

Last updated September 1, 2026

AI crawler reads

3requests

1companies
  • Anthropic3
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

Since Oct 28, 2026 · from this site's server log

Overview

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.

History

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.

Recent events

  • Reported

    Lyell appoints Richard Sherry as senior vice president[5]

    Lyell Immunopharma announced Richard Sherry's appointment as Senior Vice President, TIL Specialist and Clinical Lead.

  • Reported

    Sonoma Biotherapeutics raises $40 million in Series A funding[6]

    Sonoma Biotherapeutics launched with $40 million in Series A financing from an investor syndicate that included Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures and 8VC.

  • Reported

    Sonoma Biotherapeutics and Lyell Immunopharma enter strategic partnership[6]

    Sonoma Biotherapeutics entered into a strategic partnership with Lyell Immunopharma, providing both parties access to technologies and know-how to enhance cell therapies in their respective areas of focus.

Read more

Sources7 sources

Cite this profile: Cite the canonical profile. /brand-wiki/lyell-immunopharma · Editorial policy · How profiles are compiled